Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.5 Billion INR | -6.38% |
| 2022 | 12.28 Billion INR | 4.87% |
| 2021 | 11.71 Billion INR | 37.42% |
| 2020 | 8.52 Billion INR | -7.73% |
| 2019 | 9.24 Billion INR | 0.5% |
| 2018 | 9.19 Billion INR | -1.4% |
| 2017 | 9.32 Billion INR | 21.63% |
| 2016 | 7.66 Billion INR | 2.94% |
| 2015 | 7.44 Billion INR | 7.35% |
| 2014 | 6.93 Billion INR | 15.86% |
| 2013 | 5.98 Billion INR | 16.94% |
| 2012 | 5.12 Billion INR | 17.42% |
| 2011 | 4.36 Billion INR | 21.05% |
| 2010 | 3.6 Billion INR | 32.16% |
| 2009 | 2.72 Billion INR | -2.56% |
| 2008 | 2.79 Billion INR | -8.3% |
| 2007 | 3.05 Billion INR | 14.61% |
| 2006 | 2.66 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 11.51 Billion INR | 189.84% |
| 2024 Q1 | -12.81 Billion INR | -211.44% |
| 2023 Q4 | 11.5 Billion INR | 0.0% |
| 2023 FY | 11.5 Billion INR | -6.38% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 11.42 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 11.59 Billion INR | 0.0% |
| 2022 FY | 12.28 Billion INR | 4.87% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 12.28 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 9.59 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 11.71 Billion INR | 0.0% |
| 2021 FY | 11.71 Billion INR | 37.42% |
| 2020 Q2 | 9.3 Billion INR | 0.0% |
| 2020 Q4 | 8.52 Billion INR | 0.0% |
| 2020 FY | 8.52 Billion INR | -7.73% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q4 | 9.24 Billion INR | 0.0% |
| 2019 Q2 | 9.39 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 9.24 Billion INR | 0.5% |
| 2018 Q4 | 9.19 Billion INR | 0.0% |
| 2018 Q2 | 9.47 Billion INR | 0.0% |
| 2018 FY | 9.19 Billion INR | -1.4% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q2 | 8.41 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 9.32 Billion INR | 21.63% |
| 2017 Q4 | 9.32 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 7.66 Billion INR | 2.94% |
| 2016 Q4 | 7.66 Billion INR | 0.0% |
| 2016 Q2 | 7.37 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q4 | 7.44 Billion INR | 0.0% |
| 2015 FY | 7.44 Billion INR | 7.35% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 7.91 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 6.45 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 6.93 Billion INR | 0.0% |
| 2014 FY | 6.93 Billion INR | 15.86% |
| 2013 FY | 5.98 Billion INR | 16.94% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 5.98 Billion INR | 0.0% |
| 2013 Q2 | 5.51 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q2 | 9.14 Billion INR | 0.0% |
| 2012 FY | 5.12 Billion INR | 17.42% |
| 2012 Q4 | 5.12 Billion INR | 0.0% |
| 2011 FY | 4.36 Billion INR | 21.05% |
| 2010 FY | 3.6 Billion INR | 32.16% |
| 2009 FY | 2.72 Billion INR | -2.56% |
| 2008 FY | 2.79 Billion INR | -8.3% |
| 2007 FY | 3.05 Billion INR | 14.61% |
| 2006 FY | 2.66 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 29.31% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 92.442% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -122.046% |
| Granules India Limited | 22.95 Billion INR | 49.883% |
| Indoco Remedies Limited | 10.34 Billion INR | -11.233% |
| Achyut Healthcare Limited | 2.01 Million INR | -571385.345% |
| Ajanta Pharma Limited | 10.71 Billion INR | -7.411% |
| Alkem Laboratories Limited | 48.6 Billion INR | 76.332% |
| Alpa Laboratories Limited | 307.12 Million INR | -3645.743% |
| Brooks Laboratories Limited | 248.6 Million INR | -4527.495% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -214.222% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -136.335% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -445.51% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 89.245% |
| Eris Lifesciences Limited | 38.26 Billion INR | 69.938% |
| FDC Limited | 3.7 Billion INR | -210.147% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 82.332% |
| Gufic Biosciences Limited | 5.59 Billion INR | -105.436% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -402.476% |
| Ipca Laboratories Limited | 33.74 Billion INR | 65.907% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -3776.533% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -286.83% |
| Lasa Supergenerics Limited | 541.92 Million INR | -2022.803% |
| Laurus Labs Limited | 42.71 Billion INR | 73.068% |
| Lupin Limited | 96.23 Billion INR | 88.046% |
| Mankind Pharma Limited | 23.87 Billion INR | 51.815% |
| Medicamen Biotech Limited | 940.36 Million INR | -1123.352% |
| Medico Remedies Limited | 438.24 Million INR | -2525.022% |
| Megasoft Limited | 1.85 Billion INR | -520.783% |
| NATCO Pharma Limited | 10.53 Billion INR | -9.229% |
| Piramal Pharma Limited | 74 Billion INR | 84.455% |
| RPG Life Sciences Limited | 1.38 Billion INR | -733.502% |
| Sigachi Industries Limited | 2.53 Billion INR | -354.476% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 93.733% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -465.521% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -887.289% |
| Unichem Laboratories Limited | 8.06 Billion INR | -42.566% |
| Wanbury Limited | 3.15 Billion INR | -264.568% |
| Windlas Biotech Limited | 1.76 Billion INR | -552.635% |
| ZIM Laboratories Limited | 2.08 Billion INR | -452.874% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 83.976% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -195.512% |
| Divi's Laboratories Limited | 18.99 Billion INR | 39.421% |
| Hester Biosciences Limited | 3.59 Billion INR | -220.025% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -349.164% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1367.676% |
| Bal Pharma Limited | 2.51 Billion INR | -358.094% |
| Strides Pharma Science Limited | 37.68 Billion INR | 69.47% |
| Venus Remedies Limited | 1.39 Billion INR | -725.962% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -39.431% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -2.549% |
| Shilpa Medicare Limited | 12.93 Billion INR | 11.046% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -81.769% |
| Suven Life Sciences Limited | 148.62 Million INR | -7640.494% |
| Ind-Swift Limited | 13.45 Billion INR | 14.487% |
| Valiant Laboratories Limited | 1.05 Billion INR | -987.068% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -7.434% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 18.664% |
| Themis Medicare Limited | 1.88 Billion INR | -509.48% |
| Hikal Limited | 12.99 Billion INR | 11.473% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 85.979% |
| Sequent Scientific Limited | 8.27 Billion INR | -39.034% |
| Novartis India Limited | 1.8 Billion INR | -538.721% |
| Wockhardt Limited | 39.87 Billion INR | 71.146% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 81.225% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -3883.393% |
| Neuland Laboratories Limited | 5.49 Billion INR | -109.218% |
| Morepen Laboratories Limited | 4.45 Billion INR | -157.949% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1686.66% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -482.095% |